These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

55 related articles for article (PubMed ID: 9766573)

  • 21. Anti-tumorigenic effect of a K-ras ribozyme against human lung cancer cell line heterotransplants in nude mice.
    Zhang YA; Nemunaitis J; Scanlon KJ; Tong AW
    Gene Ther; 2000 Dec; 7(23):2041-50. PubMed ID: 11175317
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Induction of apoptosis in human esophageal cancer cells by sequential transfer of the wild-type p53 and E2F-1 genes: involvement of p53 accumulation via ARF-mediated MDM2 down-regulation.
    Itoshima T; Fujiwara T; Waku T; Shao J; Kataoka M; Yarbrough WG; Liu TJ; Roth JA; Tanaka N; Kodama M
    Clin Cancer Res; 2000 Jul; 6(7):2851-9. PubMed ID: 10914734
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Biological activity of human N-ras and K-ras genes containing the Asn17 dominant negative mutation.
    Kaplan JB
    Oncol Res; 1994; 6(12):611-5. PubMed ID: 7787254
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Epidermal growth factor inhibits the growth of TE8 esophageal cancer cells through the activation of STAT1.
    Ichiba M; Miyazaki Y; Kitamura S; Kiyohara T; Shinomura Y; Matsuzawa Y
    J Gastroenterol; 2002; 37(7):497-503. PubMed ID: 12162406
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Expression of dominant negative Erk2 inhibits AP-1 transactivation and neoplastic transformation.
    Watts RG; Huang C; Young MR; Li JJ; Dong Z; Pennie WD; Colburn NH
    Oncogene; 1998 Dec; 17(26):3493-8. PubMed ID: 10030673
    [TBL] [Abstract][Full Text] [Related]  

  • 26. SCH 51344 inhibits ras transformation by a novel mechanism.
    Kumar CC; Prorock-Rogers C; Kelly J; Dong Z; Lin JJ; Armstrong L; Kung HF; Weber MJ; Afonso A
    Cancer Res; 1995 Nov; 55(21):5106-17. PubMed ID: 7585559
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Antitumor effect of gefitinib ('Iressa') on esophageal squamous cell carcinoma cell lines in vitro and in vivo.
    Hara F; Aoe M; Doihara H; Taira N; Shien T; Takahashi H; Yoshitomi S; Tsukuda K; Toyooka S; Ohta T; Shimizu N
    Cancer Lett; 2005 Aug; 226(1):37-47. PubMed ID: 16004931
    [TBL] [Abstract][Full Text] [Related]  

  • 28. pERK activation in esophageal carcinomas: clinicopathological associations.
    Tasioudi KE; Saetta AA; Sakellariou S; Levidou G; Michalopoulos NV; Theodorou D; Patsouris E; Korkolopoulou P
    Pathol Res Pract; 2012 Jul; 208(7):398-404. PubMed ID: 22658382
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Effect of a dominant negative ras on myocardial hypertrophy by using adenoviral-mediated gene transfer.
    Pracyk JB; Hegland DD; Tanaka K
    Surgery; 1997 Aug; 122(2):404-10; discussion 410-1. PubMed ID: 9288147
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Inhibition of oncogenic K-ras signaling by aerosolized gene delivery in a mouse model of human lung cancer.
    Lee HY; Suh YA; Lee JI; Hassan KA; Mao L; Force T; Gilbert BE; Jacks T; Kurie JM
    Clin Cancer Res; 2002 Sep; 8(9):2970-5. PubMed ID: 12231543
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Biochemical characterization of a novel KRAS insertion mutation from a human leukemia.
    Bollag G; Adler F; elMasry N; McCabe PC; Conner E; Thompson P; McCormick F; Shannon K
    J Biol Chem; 1996 Dec; 271(51):32491-4. PubMed ID: 8955068
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Ethyl gallate as a novel ERK1/2 inhibitor suppresses patient-derived esophageal tumor growth.
    Liu F; Zu X; Xie X; Liu K; Chen H; Wang T; Liu F; Bode AM; Zheng Y; Dong Z; Kim DJ
    Mol Carcinog; 2019 Apr; 58(4):533-543. PubMed ID: 30499613
    [TBL] [Abstract][Full Text] [Related]  

  • 33. The significance of Ras guanine nucleotide exchange factor, son of sevenless protein, in renal cell carcinoma cell lines.
    Shinohara N; Ogiso Y; Tanaka M; Sazawa A; Harabayashi T; Koyanagi T
    J Urol; 1997 Sep; 158(3 Pt 1):908-11. PubMed ID: 9258117
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Vaccinia virus expression of p21 rasAsn-17.
    de Vries-Smits AM; Burgering BM; Bos JL
    Methods Enzymol; 1995; 255():221-9. PubMed ID: 8524105
    [No Abstract]   [Full Text] [Related]  

  • 35. Adenovirus-mediated gene transfer of dominant negative Ha-Ras inhibits proliferation of primary meningioma cells.
    Shu J; Lee JH; Harwalkar JA; Oh-Siskovic S; Stacey DW; Golubić M
    Neurosurgery; 1999 Mar; 44(3):579-87; discussion 587-8. PubMed ID: 10069595
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Sensitization against anticancer drugs by transfection with UBE2I variant gene into ras-NIH3H3 mouse fibroblasts.
    Shiratori T; Shimada H; Kagaya A; Kuboshima M; Nabeya Y; Machida T; Goto K; Takiguchi M; Ochiai T; Hiwasa T
    Anticancer Res; 2007; 27(5A):3227-33. PubMed ID: 17970065
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Inducible expression of Ras N17 dominant inhibitory protein.
    Cai H; Cooper GM
    Methods Enzymol; 1995; 255():230-7. PubMed ID: 8524106
    [No Abstract]   [Full Text] [Related]  

  • 38.
    Sasaki E; Matsushita H; Masago K; Hanai N
    Int J Surg Pathol; 2024 Sep; 32(6):1232-1233. PubMed ID: 38166486
    [No Abstract]   [Full Text] [Related]  

  • 39. P53 tumor-suppressor gene and cyclic adenosine-monophosphate in breast and esophageal cancer are regulated through high-concentration of epidermal growth-factor.
    Murayama Y
    Int J Oncol; 1993 Nov; 3(5):873-9. PubMed ID: 21573446
    [TBL] [Abstract][Full Text] [Related]  

  • 40. A preliminary study on ras protein expression in human esophageal cancer and precancerous lesions.
    Li J; Feng CW; Zhao ZG; Zhou Q; Wang LD
    World J Gastroenterol; 2000 Apr; 6(2):278-280. PubMed ID: 11819576
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 3.